Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Nov 28, 2020 12:32 AM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

November 23, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the company will participate in the following

Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat

November 15, 2020

- Results of long-term treatment from the ITCH and IMAGINE II studies presented in late-breaking oral presentation at AASLD - Data demonstrates significant and durable improvements in pruritus in children with Alagille syndrome through 220 weeks of maralixibat treatment - Results have been included

Mirum Pharmaceuticals Presents New Data From Its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting

November 13, 2020

Maralixibat data highlights the relationship between the reduction of serum bile acids and pruritus intensity, improved growth, and other quality of life measures. Analysis of the natural variability of pruritus in children with Alagille syndrome demonstrates persistent severity.

Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day

November 12, 2020

- Initiated rolling NDA submission and launched Expanded Access Program for maralixibat in Alagille syndrome. - Presented five-year transplant-free survival data for patients with PFIC2 at Digital International Liver Congress (EASL). - European Marketing Authorization Application submission for